Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics, Inc. announced that it has granted inducement awards consisting of options to purchase 92,200 shares of its common stock to four new employees. These awards vest over four years, with 25% on the first anniversary and the remainder in three equal annual installments, contingent on continued employment. The grants were approved by the Company's Compensation Committee and are in accordance with Nasdaq Rule 5635(c)(4).
Four new Zevra employees receive stock options that vest over four years
Zevra Therapeutics announced it granted stock options to purchase an aggregate of 92,200 common shares to four new employees. These inducement awards, approved by the Company's Compensation Committee, vest over four years, with 25% vesting after the first year and the remainder in three equal annual installments, contingent on continued employment. This action aligns with Nasdaq Rule 5635(c)(4) and is intended to incentivize new hires.
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company recently reported strong quarterly earnings, beating both EPS and revenue estimates, and institutional investors hold a substantial stake in the stock.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages
Zevra Therapeutics (NASDAQ:ZVRA) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $27.14, significantly higher than its current share price of $11.57. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Institutional ownership is at 35.03%, though one director recently sold a substantial number of shares.
Zevra Therapeutics (ZVRA) insider sells 42,666 shares
Zevra Therapeutics (ZVRA) Chief Legal & Compliance officer, Rahsaan Thompson, sold 42,666 shares of common stock on August 14, 2026, through a Rule 10b5-1(c) trading plan. The sale was executed at a weighted average price of $11.1277 per share, with prices ranging from $10.86 to $11.36. Following this transaction, Thompson directly holds 37,569 shares of the company.
Price-Driven Insight from (ZVRA) for Rule-Based Strategy
This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short setup.
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker
An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous 10b5-1 sales by Rahsaan Thompson, including 34,557 common shares sold for over $438,000 in June 2026.
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position
Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is based on 59,115,084 shares of Zevra common stock outstanding as of May 1, 2026.
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics
Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, realizing a value of $77,859. The transaction was reported in an SEC filing on August 12. Zevra Therapeutics shows positive revenue trends with a 53.25% growth as of June 30, 2026, and strong financial metrics like a 96.16% gross margin and low debt-to-equity ratio, despite its market capitalization being below industry benchmarks.
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA
This article provides a financial overview of Zevra Therapeutics, Inc. (FWB:1GDA) on the Frankfurt Stock Exchange, focusing on its price-to-earnings forward metric. It highlights that the market is currently closed with no trades. The content is sourced from FactSet and ICE Data Services.
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics
Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, valued at $77,859, according to a recent SEC filing. The company's financials show a positive revenue trend with 53.25% growth, a high gross margin of 96.16%, but a declining EPS of 0.14. Despite ZVRA shares being down by 1.57% at $11.3 following the news, the company maintains a low debt-to-equity ratio and an impressive EV/EBITDA ratio.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (ZVRA) following a significant stock price drop. The investigation stems from the European Medicines Agency's negative opinion on Zevra's Marketing Authorization Application for arimoclomol, a drug for Niemann-Pick disease type C. Investors who suffered losses are encouraged to contact the firm.
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock
Zevra Therapeutics Director Corey Michael Watton sold 12,300 shares of the company's stock for $138,375.00, reducing his holdings by 87.23% to 1,800 shares. This transaction follows a strong quarterly earnings report where ZVRA exceeded both EPS and revenue estimates. Analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target of $27.14 despite one recent price target cut.
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA
Dimensional Fund Advisors LP significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 259.2% in the first quarter, purchasing an additional 400,336 shares to bring its total holdings to 554,802 shares valued at $5.168 million. Other institutional investors also adjusted their positions in Zevra Therapeutics, with several increasing their holdings. The article also provides an overview of Zevra Therapeutics' stock performance, recent earnings, and current analyst ratings, which average a "Moderate Buy."
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Zevra Therapeutics, Inc. (ZVRA) on behalf of investors who purchased its securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in Zevra's stock price. The firm encourages affected shareholders to connect through its website to assist with the investigation, which is conducted on a contingency fee basis.
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data
Zevra Therapeutics' stock (ZVRA) rose 21.6% following strong Q2 2026 sales of US$39.66 million, driven by high uptake of its Niemann-Pick disease type C therapy, MIPLYFFA. New four-year real-world data for arimoclomol (MIPLYFFA's active ingredient) could be crucial for European regulatory re-examination, potentially reshaping the investment narrative beyond recent negative headlines. Despite a low earnings multiple, the stock remains sensitive to regulatory decisions and MIPLYFFA's market momentum, with ongoing legal scrutiny posing a key risk.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings with registered attendees. A live webcast will be accessible via the company's investor relations website.
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?
Zevra Therapeutics (ZVRA) has released new long-term real-world safety and effectiveness data for arimoclomol in adults with Niemann-Pick disease type C, aiming to support its equity story and regulatory efforts in Europe. This data will be crucial as the company seeks a re-examination of a negative EMA opinion. Investors are watching closely how the European Medicines Agency (EMA) responds to Zevra's request for re-examination, as regulatory decisions will impact the company's prospects for European revenue.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (NASDAQ: ZVRA) and its officers/directors. This investigation follows a negative opinion from the European Medicines Agency's CHMP regarding Zevra's Marketing Authorization Application for arimoclomol, which caused a significant drop in the company's stock price on July 24, 2026. Investors who believe they have been affected are encouraged to contact the firm.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in the company's stock price. The firm encourages affected investors to contact them to assist with the investigation, which is conducted on a contingency fee basis.
Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure
FMR LLC and Abigail P. Johnson have disclosed an 8.3% beneficial ownership stake in Zevra Therapeutics (ZVRA) through a Schedule 13G/A filing. FMR LLC has sole voting power over 4,899,562 shares and sole dispositive power over 4,915,717 shares, while Abigail P. Johnson holds sole dispositive power over the same 4,915,717 shares, indicating her control relation to FMR LLC. This filing outlines the ownership structure and confirms that no other single person has an interest exceeding five percent of the outstanding common stock.
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside
Zevra Therapeutics, Inc. (ZVRA) has seen its average 12-month price target increase from $24.78 to $25.11, according to estimates from nine analysts. This updated target implies a significant 138% potential upside from the August 5 closing price, with individual forecasts ranging from $20 to $35 per share. The consensus rating from all nine covering analysts remains a "Buy."
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. (NASDAQ: ZVRA) following a sharp drop in its stock price. The decline occurred after the European Medicines Agency's CHMP issued a negative opinion on Zevra's Marketing Authorization Application for arimoclomol, branded Meplyffa. The firm encourages ZVRA stockholders to contact them to assist with the investigation, which is conducted on a contingency fee basis.
ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54
Zevra Therapeutics (NASDAQ: ZVRA) appears significantly undervalued according to GuruFocus' GF Value™, trading at $10.54, which is 54.4% below its intrinsic value estimate of $23.11. Despite strong Q2 2026 revenue growth driven by its product MIPLYFFA, the company's GF Score™ of 64/100 indicates moderate overall quality with strong financial strength but weaker profitability and a "Possible Value Trap" caution. Insider selling transactions totaling $0.5 million in the past three months further suggest a nuanced investment profile requiring thorough due diligence.
Zevra Therapeutics Reports Strong Q2 2026 Earnings with Growth in MIPLYFFA
Zevra Therapeutics announced robust Q2 2026 earnings, reporting $39.7 million in net revenue, a 53% year-over-year increase, largely driven by $30.2 million in U.S. sales of MIPLYFFA. The company also strengthened MIPLYFFA's intellectual property with an Orange Book listing extending to 2041. Despite strong U.S. performance, Zevra faces challenges in Europe due to a negative CHMP opinion on arimoclomol, prompting a reexamination process.
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) reported strong Q2 results, with earnings of $0.25 per share significantly beating the Zacks Consensus Estimate of $0.08, and revenues of $39.66 million surpassing estimates by 22.76%. Despite this positive performance and a 17.4% year-to-date stock increase, the company currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revision trends. Investors are advised to monitor future estimate changes and management commentary for insights into the stock's future trajectory.
ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary
Zevra Therapeutics, Inc. reported strong financial results for the quarter ended 2026, with revenue reaching $39.66M and diluted EPS of $0.14, primarily driven by the commercialization of MIPLYFFA. The company highlighted significant revenue growth, successful market penetration for MIPLYFFA, and ongoing progress in its clinical trials, alongside strategic financial and regulatory initiatives.
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics reported strong second-quarter 2026 financial results, with $39.7 million in net revenue, a 53% increase over Q2 2025, primarily driven by MIPLYFFA sales. The company achieved a net income of $8.8 million and maintained a robust cash position of $260.2 million, which it believes is sufficient to execute its strategic priorities without relying on capital markets. Zevra also provided updates on its pipeline, including progress in the DiSCOVER trial for celiprolol and ongoing efforts to gain European approval for arimoclomol.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will deliver the presentation, and management will also be available for one-on-one meetings with registered conference attendees. A live webcast of the presentation will be accessible on the "Events & Presentations” page of Zevra’s investor relations website.
Zevra executives set to present at Boston growth conference
Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings, and a live webcast of the presentation will be accessible via the Investor Relations section of Zevra's website. The company, focused on rare diseases, plans to discuss its progress, pipeline, and efforts to broaden access to its life-changing therapies, including its lead product for Niemann-Pick disease type C.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will present and be available for one-on-one meetings with registered attendees. A live webcast link will be available on the Investor Relations section of Zevra’s website.
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky has initiated a securities investigation into Zevra Therapeutics (ZVRA) following a significant 24% stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa. The investigation focuses on whether Zevra made misleading public statements regarding arimoclomol's approval status, specifically a May 2024 statement by CEO Neil McFarlane.
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has issued a securities investigation notice for Zevra Therapeutics (NASDAQ: ZVRA) following a 24% stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. The investigation focuses on potential misstatements made by Zevra, particularly a May 2024 earnings call statement by CEO Neil McFarlane regarding arimoclomol's anticipated status as the "only approved foundational therapy" for NPC.
Zevra Therapeutics Announces Publication of 4-Year Real-World Data on MIPLYFFA in Niemann-Pick Disease Type C
Zevra Therapeutics has announced the publication of 4-year real-world data on its drug MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) in Molecular Genetics and Metabolism. The study, involving 109 participants, demonstrated long-term safety and effectiveness, showing stable disease severity over time, particularly for adults with NPC. MIPLYFFA, FDA-approved since September 2024, is indicated for neurological manifestations of NPC in combination with miglustat, and Zevra is pursuing geographic expansion and further regulatory approvals.
Zevra's First Published Adult Niemann-Pick Data Includes Up to 4 Years
Zevra Therapeutics announced the publication of four-year real-world data from its U.S. Early Access Program for MIPLYFFA (arimoclomol) in Niemann-Pick disease type C (NPC). The study, detailed in Molecular Genetics and Metabolism, followed 109 participants, including 53 adults, and showed that disease severity remained relatively stable over time with safety findings consistent with MIPLYFFA's established profile. This publication includes the first real-world data for arimoclomol in adult NPC patients and adds to over five years of global clinical experience.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Zevra Therapeutics, Inc. (ZVRA) following a negative opinion from the European Medicines Agency regarding its drug, arimoclomol, which caused a sharp drop in Zevra's stock price. The firm is encouraging investors who purchased Zevra securities to join their investigation to potentially recover losses. Bronstein, Gewirtz & Grossman, LLC represents investors in class actions on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Zevra Therapeutics announced the publication of four-year real-world data from its U.S. Early Access Program for MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC). The longitudinal study, published in Molecular Genetics and Metabolism, evaluated arimoclomol in a broad US NPC population, including the first published real-world data for adults with NPC, showing stable disease severity scores and a safety profile consistent with prior findings. MIPLYFFA is Zevra’s FDA-approved therapy for NPC, demonstrating long-term clinical outcomes across over 270 patients globally.
Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA)
This article provides recent news headlines related to Zevra Therapeutics, Inc. (ZVRA), including multiple investor alerts about investigations into the company. It also mentions a presentation of new data and a resubmission of a New Drug Application to the FDA. The stock's current delayed price and performance are also displayed.
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency's CHMP regarding the Marketing Authorization Application for arimoclomol, which caused a sharp drop in Zevra's stock price. The firm encourages affected investors to contact them to assist in the investigation, noting they operate on a contingency fee basis.
Zevra Therapeutics Market Sentiment
This article provides an overview of Zevra Therapeutics (ZVRA) market sentiment, including analyst consensus, short interest, and recent insider activity. It highlights that 15 analysts have a "Buy" consensus with an average price target of $23, and mentions several recent insider acquisitions of stock options. The company's short float is 11.1% and declining, which is considered bullish.
Vanguard Capital Management (ZVRA) discloses 3.0M-share Zevra Therapeutics position on 13G
Vanguard Capital Management has filed a Schedule 13G, disclosing a passive ownership stake of 3,024,980 shares in Zevra Therapeutics Inc (ZVRA), representing 5.11% of the outstanding common stock. Vanguard holds sole voting power over 386,070 shares and sole dispositive power over all 3,024,980 shares, with no shared voting or dispositive power reported. This filing indicates the shares are held in Vanguard funds and managed accounts, and no single other person's interest exceeds 5% through these holdings.
Zevra Therapeutics Inc (ZVRA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Zevra Therapeutics Inc (ZVRA), highlighting its current valuation score and P/E ratio within the Pharmaceuticals industry. It notes that the company's valuation score is 7.58, ranking 120 out of 155, and its P/E ratio is 4.57, which is significantly below its recent high and above its recent low. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Zevra Therapeutics (ZVRA) Stock Forum and Discussion
This article provides a platform for discussion and a forum for investors interested in Zevra Therapeutics (ZVRA) stock. It serves as a central point for sharing insights, news, and analysis related to the company's performance and future outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (NASDAQ: ZVRA) on behalf of investors. This investigation follows a 23.92% stock price drop on July 24, 2026, after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion regarding Zevra's Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C. Investors who suffered losses are encouraged to contact Pomerantz LLP.
Levi & Korsinsky Announces Investigation of Securities Claims Against Zevra Therapeutics, Inc. (ZVRA)
Levi & Korsinsky has initiated an investigation into Zevra Therapeutics, Inc. (ZVRA) following a significant 24% pre-market stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, Zevra's lead product for Niemann-Pick disease type C. The firm is inviting investors who suffered losses to explore potential recovery under federal securities laws.
Zevra Therapeutics, Inc. (ZVRA) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky has launched an investigation into Zevra Therapeutics, Inc. (ZVRA) following a significant pre-market stock drop on July 24, 2026. This decline was triggered by a negative opinion from the European Medicines Agency regarding arimoclomol, Zevra's lead product for Niemann-Pick disease type C. The firm is inviting investors who suffered losses to explore potential recovery under federal securities laws.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. (ZVRA) after the company received a negative opinion from the European Medicines Agency regarding its drug arimoclomol, leading to a sharp drop in stock price. The firm encourages Zevra investors who are aware of relevant facts or who purchased Zevra securities to connect with them for potential class action involvement, emphasizing no upfront cost to investors.
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics
SueWallSt, powered by Levi & Korsinsky LLP, is investigating potential securities claims against Zevra Therapeutics (NASDAQ: ZVRA) following a significant stock drop on July 24, 2026. The decline occurred after the European Medicines Agency's CHMP issued a negative opinion on Zevra's drug arimoclomol for Niemann-Pick disease type C. The investigation focuses on whether Zevra made misleading statements about the drug's regulatory prospects before this announcement.
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
This article provides a comprehensive roundup of U.S. Wall Street securities analysts' revised ratings and price targets for numerous U.S.-listed companies, including major players like Blackstone, Hartford Insurance, and Zevra Therapeutics. The report details upgrades, downgrades, and new coverage initiations from various firms, offering insights into analyst sentiment across diverse sectors.
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Zevra Therapeutics, Inc. (NASDAQ: ZVRA) for potential securities law violations after Zevra received a negative opinion from the European Medicines Agency regarding its drug arimoclomol (Meplyffa), causing its shares to fall significantly. SBS is inviting shareholders who experienced losses to participate in the investigation to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation.
